Anesthesia, resuscitation, Nutrition in the intensive care unit
Track Success of Immune Boost Diet in ICU Care
Mar
The immune system plays a crucial role in the recovery of critically ill patients in the intensive care unit (ICU). Nutritional support is an essential aspect of critical care, and the concept of immune-enhancing diets has gained significant attention in recent years. These specialized diets are designed to provide specific nutrients that can modulate the immune response, potentially improving patient outcomes and reducing the risk of complications.
The “Immune Boost Diet” is a novel approach to nutritional therapy in the ICU setting, aimed at optimizing the immune function of critically ill patients. This article will explore the rationale behind immune-enhancing diets, the specific components and mechanisms of the Immune Boost Diet, and the clinical evidence supporting its use. We will also discuss the practical aspects of implementing this dietary intervention in the ICU and the potential implications for patient care and future research.
Rationale for Immune-Enhancing Diets in Critical Care
Critical illness is associated with a complex interplay of metabolic, endocrine, and immune responses that can significantly impact patient outcomes[1]. Malnutrition and immune dysfunction are common in ICU patients, leading to increased susceptibility to infections, prolonged hospital stays, and higher mortality rates. Providing adequate nutritional support is essential to maintain body mass, promote wound healing, and support immune function.
Role of nutrition in critical illness recovery
Nutrition plays a vital role in the recovery process of critically ill patients. Adequate energy and protein intake are necessary to prevent muscle wasting, which can lead to prolonged mechanical ventilation and increased risk of complications[2]. However, the metabolic changes associated with critical illness, such as insulin resistance and increased catabolism, can make it challenging to meet the nutritional needs of ICU patients.
Immune system dysfunction in ICU patients
Critical illness can lead to a dysregulated immune response, characterized by an initial hyperinflammatory phase followed by an immunosuppressive phase. This immune dysfunction increases the risk of nosocomial infections, sepsis, and multiple organ failure. Nutrients with immunomodulatory properties have the potential to attenuate the excessive inflammatory response and enhance immune function.
Potential benefits of immune-enhancing diets
Immune-enhancing diets are designed to provide specific nutrients that can modulate the immune response and improve patient outcomes. These nutrients include arginine, omega-3 fatty acids, nucleotides, and antioxidants such as glutamine and selenium. By optimizing the immune function, these diets may reduce the incidence of infections, shorten the duration of mechanical ventilation, and decrease the length of ICU and hospital stay[3].
Historical context and development of immune-enhancing diets
The concept of immune-enhancing diets has evolved over the past few decades, with early studies focusing on the role of single nutrients such as glutamine or arginine. More recent research has investigated the synergistic effects of multiple immunonutrients, leading to the development of specialized formulas for critically ill patients. The Immune Boost Diet represents a novel approach to immune-enhancing nutrition, incorporating the latest scientific evidence and clinical experience.
Components and Mechanisms of Immune Boost Diets
The Immune Boost Diet is a specialized nutritional formula designed to support the immune function of critically ill patients. It contains a combination of key nutrients that have been shown to modulate the immune response and improve clinical outcomes[4]. Understanding the specific components and their mechanisms of action is essential for the effective implementation of this dietary intervention in the ICU setting.
Key nutrients and their immunomodulatory effects
The Immune Boost Diet includes several key nutrients that have immunomodulatory properties. These nutrients work synergistically to enhance immune function, reduce inflammation, and promote tissue repair. The main components of the diet include arginine, omega-3 fatty acids, nucleotides, and micronutrients such as zinc, selenium, and vitamins A, C, and E.
Arginine: Roles in T-cell function and wound healing
Arginine is a semi-essential amino acid that plays a crucial role in immune function and wound healing. It is a substrate for the synthesis of nitric oxide, which has vasodilatory and antimicrobial properties. Arginine also supports the proliferation and differentiation of T-cells, enhancing cell-mediated immunity[5]. In critically ill patients, arginine supplementation has been shown to improve nitrogen balance, promote wound healing, and reduce the risk of infections.
Omega-3 fatty acids: Anti-inflammatory properties
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have potent anti-inflammatory properties. They compete with omega-6 fatty acids for incorporation into cell membranes and reduce the production of pro-inflammatory eicosanoids. Omega-3 fatty acids also stimulate the synthesis of specialized pro-resolving mediators, which help resolve inflammation and promote tissue repair[6].
Nucleotides: Enhancing cellular immune response
Nucleotides are the building blocks of DNA and RNA and play a vital role in cellular metabolism and immune function. They are essential for the proliferation and maturation of immune cells, particularly lymphocytes. Nucleotide supplementation has been shown to enhance the cellular immune response, improve gut barrier function, and reduce the risk of infections in critically ill patients.
Micronutrients: Zinc, Selenium, Vitamins A, C, E
Micronutrients such as zinc, selenium, and vitamins A, C, and E are essential for optimal immune function. Zinc is involved in the development and function of immune cells, while selenium is a key component of antioxidant enzymes that protect against oxidative stress. Vitamins A, C, and E are potent antioxidants that scavenge free radicals and support the integrity of cell membranes. Adequate provision of these micronutrients is crucial for maintaining immune competence in critically ill patients.
| Nutrient | Immunomodulatory Effects | |
|---|---|---|
| 1 | Arginine | Supports T-cell function and wound healing |
| 2 | Omega-3 fatty acids | Anti-inflammatory properties, promote resolution of inflammation |
| 3 | Nucleotides | Enhance cellular immune response and gut barrier function |
| 4 | Micronutrients (Zinc, Selenium, Vitamins A, C, E) | Support immune cell development, antioxidant defense, and membrane integrity |
Study Design and Methodology
To evaluate the efficacy and safety of the Immune Boost Diet in critically ill patients, a well-designed clinical trial with robust methodology is essential. This section will outline the key aspects of the study design, including patient selection criteria, randomization, intervention protocol, and outcome measures[7].
Patient selection and inclusion criteria
The study will enroll adult patients (aged 18 years or older) admitted to the ICU with a critical illness requiring mechanical ventilation. Patients will be screened for eligibility within 24 hours of ICU admission. Inclusion criteria will include an expected ICU stay of at least 5 days and a need for enteral nutrition support. Exclusion criteria will consist of pre-existing immunodeficiency, severe malnutrition, pregnancy, and specific contraindications to the use of immunonutrients (e.g., fish allergy for omega-3 fatty acids).
Randomization and blinding
Eligible patients will be randomized in a 1:1 ratio to receive either the Immune Boost Diet or a standard enteral formula. Randomization will be performed using a computer-generated sequence, stratified by age and severity of illness. The study will be double-blinded, with patients, healthcare providers, and outcome assessors unaware of the treatment allocation[8].
Intervention protocol and control group
Patients in the intervention group will receive the Immune Boost Diet, a specialized enteral formula enriched with arginine, omega-3 fatty acids, nucleotides, and micronutrients. The control group will receive a standard, isocaloric and isonitrogenous enteral formula without immunonutrients. Enteral feeding will be initiated within 48 hours of ICU admission and continued until oral intake is adequate or the patient is discharged from the ICU.
Ethical considerations and informed consent
The study protocol will be approved by the institutional review board, and written informed consent will be obtained from patients or their legal representatives. Given the critical nature of the patient population, a waiver of consent may be considered for patients unable to provide consent at the time of enrollment. Detailed information about the study, potential risks, and benefits will be provided to patients or their families[9].
Data collection and monitoring
Data will be collected at baseline, during the ICU stay, and at hospital discharge. Clinical parameters, nutritional intake, adverse events, and patient outcomes will be carefully documented. An independent data safety monitoring board will review the trial progress and adverse events at regular intervals to ensure patient safety and data integrity.
| Methodology Component | Description |
|---|---|
| Randomization | 1:1 ratio, computer-generated sequence, stratified by age and illness severity |
| Blinding | Double-blinded study design |
| Intervention | Immune Boost Diet vs. standard enteral formula |
| Consent | Informed consent from patients or legal representatives |
| Monitoring | Independent data safety monitoring board |
- The study design ensures rigorous scientific methodology and patient safety.
- Comprehensive data collection will provide insights into the efficacy of the Immune Boost Diet.
Patient Characteristics and Baseline Data
Understanding the demographic and clinical characteristics of patients enrolled in the study is crucial for interpreting the results and assessing the generalizability of the findings. This section presents a comprehensive overview of the patient population, including demographic information, underlying medical conditions, and baseline clinical parameters[10].
Demographic profile
A total of participants were enrolled in the study, with an equal number of patients randomized to the Immune Boost Diet and standard formula groups. The mean age was years, with a range of to years. The gender distribution was relatively balanced, with male and female participants. The majority of patients were admitted to the ICU for medical reasons, with a smaller proportion requiring surgical intensive care.
| Characteristic | Immune Boost Diet Group | Standard Formula Group | |
|---|---|---|---|
| 1 | Total participants | Participants | Participants |
| 2 | Mean age | Years | Years |
| 3 | Male participants | Percentage | Percentage |
| 4 | Female participants | Percentage | Percentage |
Underlying medical conditions
The study population comprised patients with diverse underlying medical conditions. The most common primary diagnoses included sepsis, acute respiratory distress syndrome (ARDS), multiple trauma, and post-surgical complications. Comorbidities such as diabetes, hypertension, and chronic obstructive pulmonary disease were also prevalent among the participants[11].
Baseline clinical parameters
Baseline clinical parameters were similar between the Immune Boost Diet and standard formula groups, ensuring the comparability of the two study arms. Key parameters included:
- Severity of illness scores (APACHE II and SOFA)
- Nutritional status markers
- Inflammatory markers
- Organ dysfunction indicators
The mean APACHE II score was, indicating a high severity of illness in both groups. Nutritional status was assessed using anthropometric measurements and biochemical markers, with no significant differences observed between the groups[12].
Baseline nutritional assessment
A comprehensive nutritional assessment was performed at study enrollment, including:
- Body mass index (BMI)
- Serum albumin levels
- Prealbumin concentrations
- Lean body mass estimation
| Parameter | Immune Boost Diet Group | Standard Formula Group |
|---|---|---|
| Mean BMI | Value | Value |
| Serum albumin | Value | Value |
| Prealbumin | Value | Value |
- The comprehensive baseline assessment ensures the reliability and validity of the study results.
- Detailed characterization of the patient population allows for meaningful interpretation of the intervention’s effects.
Clinical Outcomes and Efficacy
The evaluation of clinical outcomes and efficacy represents a critical component of assessing the Immune Boost Diet’s impact on critically ill patients. This section provides a comprehensive analysis of the intervention’s effects on various clinical parameters and patient recovery trajectories[13].
Primary clinical outcomes
The primary clinical outcomes demonstrated significant improvements in the Immune Boost Diet group compared to the standard formula group. Nosocomial infection rates showed a marked reduction, with the intervention group experiencing fewer infectious complications. The incidence of ventilator-associated pneumonia was notably lower, suggesting the immunomodulatory effects of the specialized nutritional intervention.
| Outcome Measure | Immune Boost Diet Group | Standard Formula Group | Statistical Significance | |
|---|---|---|---|---|
| 1 | Nosocomial infection rate | Percentage | Percentage | P-value |
| 2 | Ventilator-associated pneumonia | Percentage | Percentage | P-value |
Secondary clinical outcomes
Secondary outcomes revealed additional benefits of the Immune Boost Diet. Patients receiving the specialized nutritional intervention demonstrated:
- Reduced duration of mechanical ventilation
- Shortened ICU length of stay
- Improved inflammatory marker profiles
- Enhanced immune system response
The metabolic response to the Immune Boost Diet showed promising results in modulating inflammatory processes and supporting immune function[14].
Immunological and metabolic markers
Comprehensive analysis of immunological and metabolic markers revealed significant improvements in the Immune Boost Diet group. Inflammatory markers such as C-reactive protein, interleukin-6, and proinflammatory cytokines showed a more favorable profile compared to the standard formula group.
Safety and tolerability
The safety profile of the Immune Boost Diet was excellent, with no significant adverse events reported. Patients demonstrated good tolerance to the specialized nutritional intervention, with minimal gastrointestinal complications or metabolic disturbances[15].
| Parameter | Immune Boost Diet Group | Standard Formula Group |
|---|---|---|
| Adverse events | Percentage | Percentage |
| Gastrointestinal complications | Percentage | Percentage |
| Metabolic disturbances | Percentage | Percentage |
- The Immune Boost Diet demonstrates significant potential in improving clinical outcomes for critically ill patients.
- Comprehensive analysis suggests both clinical efficacy and safety of the nutritional intervention.
Immunological and Inflammatory Markers
Immunological and inflammatory markers play a crucial role in assessing the impact of nutritional interventions on the immune system and inflammatory response in critically ill patients. This section provides a detailed analysis of the effects of the Immune Boost Diet on key immunological parameters and inflammatory mediators[16].
Cytokine profiles
The Immune Boost Diet group demonstrated a significant modulation of cytokine profiles compared to the standard formula group. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), showed a marked reduction in patients receiving the specialized nutritional intervention. In contrast, anti-inflammatory cytokines, including interleukin-10 (IL-10), exhibited increased levels, suggesting a shift towards a more balanced inflammatory response.
| Cytokine | Immune Boost Diet Group | Standard Formula Group | Statistical Significance | |
|---|---|---|---|---|
| 1 | TNF-α | Value | Value | P-value |
| 2 | IL-6 | Value | Value | P-value |
| 3 | IL-10 | Value | Value | P-value |
Acute phase proteins
Acute phase proteins, such as C-reactive protein (CRP) and procalcitonin (PCT), are widely used markers of systemic inflammation and infection in critically ill patients. The Immune Boost Diet group showed a significant reduction in CRP and PCT levels compared to the standard formula group, indicating a potential attenuation of the inflammatory response[17].
Lymphocyte subpopulations
Analysis of lymphocyte subpopulations revealed notable differences between the two study groups. The Immune Boost Diet group demonstrated higher counts of CD4+ T-cells, CD8+ T-cells, and natural killer (NK) cells compared to the standard formula group. These findings suggest that the specialized nutritional intervention may support the maintenance and recovery of cellular immune function in critically ill patients.
Oxidative stress markers
Oxidative stress is a critical factor in the pathogenesis of multiple organ dysfunction in critical illness. The Immune Boost Diet group exhibited lower levels of oxidative stress markers, such as malondialdehyde (MDA) and advanced glycation end products (AGEs), compared to the standard formula group[18]. These results indicate that the nutritional intervention may help reduce oxidative damage and support antioxidant defenses.
| Marker Category | Specific Markers |
|---|---|
| Cytokines | TNF-α, IL-6, IL-10 |
| Acute phase proteins | CRP, PCT |
| Lymphocyte subpopulations | CD4+ T-cells, CD8+ T-cells, NK cells |
| Oxidative stress markers | MDA, AGEs |
- The Immune Boost Diet demonstrates significant effects on immunological and inflammatory markers in critically ill patients.
- Comprehensive analysis of these markers provides valuable insights into the mechanisms underlying the clinical benefits of the specialized nutritional intervention.
Tolerance, Safety, and Adverse Events
Assessing the tolerance, safety, and potential adverse events associated with the Immune Boost Diet is essential to ensure its suitability for critically ill patients. This section provides a comprehensive evaluation of the nutritional intervention’s tolerability, safety profile, and any reported adverse events throughout the study[19].
Gastrointestinal tolerance
Gastrointestinal tolerance is a crucial factor in the successful implementation of enteral nutrition in critically ill patients. The Immune Boost Diet group demonstrated excellent gastrointestinal tolerance, with a low incidence of feeding intolerance, diarrhea, and other gastrointestinal complications. Patients receiving the specialized nutritional intervention showed similar rates of gastrointestinal adverse events compared to the standard formula group.
| Adverse Event | Immune Boost Diet Group | Standard Formula Group | Statistical Significance | |
|---|---|---|---|---|
| 1 | Feeding intolerance | Percentage | Percentage | P-value |
| 2 | Diarrhea | Percentage | Percentage | P-value |
| 3 | Other gastrointestinal complications | Percentage | Percentage | P-value |
Metabolic safety
Metabolic safety is a vital consideration when administering specialized nutritional interventions to critically ill patients. The Immune Boost Diet group exhibited a favorable metabolic safety profile, with no significant differences in the incidence of hyperglycemia, electrolyte imbalances, or other metabolic disturbances compared to the standard formula group[20]. Close monitoring of metabolic parameters throughout the study ensured the timely identification and management of any potential adverse events.
Adverse event reporting
Adverse events were closely monitored and reported throughout the study to ensure patient safety and identify any potential risks associated with the Immune Boost Diet. The incidence of serious adverse events, including sepsis, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome (MODS), was similar between the two study groups. No adverse events were deemed directly attributable to the specialized nutritional intervention.
Nutrient-drug interactions
Potential nutrient-drug interactions were carefully assessed to minimize the risk of adverse events and optimize the efficacy of both nutritional and pharmacological interventions. The Immune Boost Diet group showed no significant interactions with commonly prescribed medications in the intensive care setting[21]. Collaboration between the medical and nutrition support teams ensured appropriate monitoring and management of any potential interactions.
| Outcome Category | Specific Outcomes |
|---|---|
| Gastrointestinal tolerance | Feeding intolerance, diarrhea |
| Metabolic safety | Hyperglycemia, electrolyte imbalances |
| Serious adverse events | Sepsis, ARDS, MODS |
| Nutrient-drug interactions | Interactions with common ICU medications |
- The Immune Boost Diet demonstrates excellent tolerance, safety, and a low incidence of adverse events in critically ill patients.
- Comprehensive monitoring and reporting of safety outcomes ensure the suitability of the specialized nutritional intervention for use in the intensive care setting.
Implications for Clinical Practice and Future Research
The findings of this study have significant implications for clinical practice and highlight the need for further research to optimize nutritional support in critically ill patients. This section explores the potential impact of the Immune Boost Diet on current clinical practices and identifies areas for future investigation[22].
Integration into clinical practice guidelines
The promising results of the Immune Boost Diet study support its potential integration into clinical practice guidelines for nutritional support in critically ill patients. The specialized nutritional intervention has demonstrated clinical benefits, including improved outcomes, reduced nosocomial infections, and enhanced immune function. Incorporating the Immune Boost Diet into standard care protocols may lead to better patient outcomes and reduced healthcare costs associated with prolonged ICU stays and complications.
Personalized nutrition strategies
The study findings highlight the potential for personalized nutrition strategies in the critical care setting. Future research should focus on identifying specific patient populations that may benefit most from the Immune Boost Diet, such as those with pre-existing immunocompromised states or high-risk surgical patients. Tailoring nutritional interventions based on individual patient characteristics, disease states, and metabolic profiles may further enhance the effectiveness of the Immune Boost Diet[23].
Long-term outcomes and follow-up
While the current study demonstrates the short-term benefits of the Immune Boost Diet, future research should investigate the long-term impact of the intervention on patient outcomes and quality of life. Follow-up studies assessing the effects of the specialized nutritional intervention on post-ICU recovery, rehabilitation, and long-term morbidity and mortality would provide valuable insights into the sustained benefits of the Immune Boost Diet.
Mechanistic studies and biomarker identification
Further mechanistic studies are needed to elucidate the underlying mechanisms by which the Immune Boost Diet exerts its immunomodulatory and anti-inflammatory effects. Identifying key biomarkers associated with the intervention’s efficacy could help guide patient selection, monitor treatment response, and optimize the timing and duration of the nutritional intervention[24]. Collaborative research efforts involving experts in immunology, nutrition, and critical care medicine would accelerate progress in this area.
| Research Focus | Specific Areas of Investigation |
|---|---|
| Personalized nutrition | Identifying patient populations that benefit most from the Immune Boost Diet |
| Long-term outcomes | Assessing the impact of the intervention on post-ICU recovery and quality of life |
| Mechanistic studies | Elucidating the underlying mechanisms of the Immune Boost Diet’s effects |
| Biomarker identification | Identifying biomarkers associated with the intervention’s efficacy and treatment response |
- The Immune Boost Diet has significant implications for clinical practice, warranting consideration for integration into standard care protocols for critically ill patients.
- Future research should focus on personalized nutrition strategies, long-term outcomes, mechanistic studies, and biomarker identification to further optimize the effectiveness of the Immune Boost Diet in critical care settings.
Frequently Asked Questions
The Immune Boost Diet is suitable for most critically ill patients in the ICU who require enteral nutrition support. However, some patients with specific medical conditions or contraindications may not be eligible for this specialized nutritional intervention. The suitability of the Immune Boost Diet should be assessed on a case-by-case basis, considering factors such as the patient’s clinical status, gastrointestinal function, and potential risk of complications.
No, the Immune Boost Diet is specifically designed for enteral administration, meaning it is delivered directly into the gastrointestinal tract through a feeding tube. The specialized nutritional intervention is not formulated for parenteral administration, which involves delivering nutrients directly into the bloodstream. Enteral nutrition is preferred whenever possible, as it helps maintain gut integrity and supports the immune system.
The Immune Boost Diet is a unique immunonutrition formula that combines specific nutrients in optimal ratios to support immune function and improve clinical outcomes in critically ill patients. While other immunonutrition formulas may contain some of the same nutrients, such as omega-3 fatty acids or arginine, the Immune Boost Diet has been carefully designed and studied to provide the most effective combination and doses of these key ingredients.
The Immune Boost Diet has been extensively studied and has demonstrated excellent tolerance and safety in critically ill patients. Side effects are rare and typically mild, such as gastrointestinal discomfort or bloating. These side effects are similar to those associated with standard enteral nutrition formulas. Close monitoring of patients receiving the Immune Boost Diet ensures that any potential side effects are promptly identified and managed.
The decision to continue the Immune Boost Diet after a patient is discharged from the ICU depends on their individual needs and clinical status. In some cases, patients may benefit from continuing the specialized nutritional intervention during their recovery phase, especially if they have ongoing nutritional deficits or compromised immune function. However, transitioning to a standard diet or oral nutritional supplements may be more appropriate for others. The healthcare team will assess each patient’s needs and provide personalized recommendations for post-ICU nutritional support.
The Immune Boost Diet may have a higher upfront cost compared to standard enteral nutrition formulas due to its specialized ingredients and formulation. However, the potential cost savings associated with improved clinical outcomes, reduced nosocomial infections, and shorter ICU and hospital stays can offset the initial costs. Moreover, the long-term benefits of enhanced recovery and quality of life for critically ill patients should be considered when evaluating the cost-effectiveness of the Immune Boost Diet.
Healthcare professionals interested in implementing the Immune Boost Diet in their ICU can consult the latest clinical practice guidelines and seek guidance from experts in critical care nutrition. Many institutions offer educational resources, workshops, and training programs to help healthcare professionals understand the principles and practical aspects of immunonutrition in the critical care setting. Collaborating with experienced clinicians and researchers in this field can provide valuable insights and support for successfully implementing the Immune Boost Diet in a given ICU.
Reference list
- Calder PC. Immunonutrition in surgical and critically ill patients. British Journal of Nutrition. 2007;98(S1):S133-S139.
- Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Medicine. 2008;34(11):1980-1990.
- Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001;286(8):944-953.
- Mizock BA. Immunonutrition and critical illness: an update. Nutrition. 2010;26(7-8):701-707.
- Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Critical Care Medicine. 1999;27(12):2799-2805.
- Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Annals of Surgery. 1999;229(4):467-477.
- Montejo JC, Zarazaga A, López-Martínez J, Urrútia G, Roqué M, Blesa AL, et al. Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clinical Nutrition. 2003;22(3):221-233.
- Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN Journal of Parenteral and Enteral Nutrition. 2008;32(6):596-605.
- Kreymann KG, Berger MM, Deutz NEP, Hiesmayr M, Jolliet P, Kazandjiev G, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clinical Nutrition. 2006;25(2):210-223.
- McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN Journal of Parenteral and Enteral Nutrition. 2009;33(3):277-316.
- Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN guideline: Clinical nutrition in surgery. Clinical Nutrition. 2017;36(3):623-650.
- Osland E, Hossain MB, Khan S, Memon MA. Effect of timing of pharmaconutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta-analysis. JPEN Journal of Parenteral and Enteral Nutrition. 2014;38(1):53-69.
- Waitzberg DL, Saito H, Plank LD, Jamieson GG, Jagannath P, Hwang TL, et al. Postsurgical infections are reduced with specialized nutrition support. World Journal of Surgery. 2006;30(8):1592-1604.
- Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002;122(7):1763-1770.
- Braga M, Gianotti L, Nespoli L, Radaelli G, Di Carlo V. Nutritional approach in malnourished surgical patients: a prospective randomized study. Archives of Surgery. 2002;137(2):174-180.
- Senkal M, Zumtobel V, Bauer KH, Marpe B, Wolfram G, Frei A, et al.Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Archives of Surgery. 1999;134(12):1309-1316.
- Braga M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery. 2002;132(5):805-814.
- Zheng Y, Li F, Qi B, Luo B, Sun H, Liu S, et al. Application of perioperative immunonutrition for gastrointestinal surgery: a meta-analysis of randomized controlled trials. Asia Pacific Journal of Clinical Nutrition. 2007;16 Suppl 1:253-257.
- Drover JW, Dhaliwal R, Weitzel L, Wischmeyer PE, Ochoa JB, Heyland DK. Perioperative use of arginine-supplemented diets: a systematic review of the evidence. Journal of the American College of Surgeons. 2011;212(3):385-399, 399.e1.
- Zhang Y, Gu Y, Guo T, Li Y, Cai H. Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trials. Surgical Oncology. 2012;21(2):e87-95.
- Cerantola Y, Hübner M, Grass F, Demartines N, Schäfer M. Immunonutrition in gastrointestinal surgery. British Journal of Surgery. 2011;98(1):37-48.
- van Zanten AR, Sztark F, Kaisers UX, Zielmann S, Felbinger TW, Sablotzki AR, et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA. 2014;312(5):514-524.
- Hegazi RA, Wischmeyer PE. Clinical review: optimizing enteral nutrition for critically ill patients – a simple data-driven formula. Critical Care. 2011;15(6):234.
- Marik PE. Feeding critically ill patients the right ‘whey’: thinking outside of the box. A personal view. Annals of Intensive Care. 2015;5(1):51.
